Literature DB >> 26722421

Amplification of chromosome 8q21-qter associated with the acquired paclitaxel resistance of nasopharyngeal carcinoma cells.

Wei Li1, Yating You1, Xiaowei Zhang1, Yexun Song1, Hong Xiang2, Xiaowei Peng3, Jiangbo Qin4, Guolin Tan1.   

Abstract

OBJECTIVE: to observe relationship between chromosome imbalance and taxol resistance in nasopharyngeal carcinoma (NPC).
METHODS: three taxol-resistant sub-lines were established through repeated exposure of escalating doses of paclitaxel to NPC cell lines (CNE-1, HNE-2 and 5-8F). The change of copy number of chromosomes was investigated by the genome-wide analyses of comparative genomic hybridization (CGH). Gene profiles of both parental and resistant cell lines were determined by cDNA microarray. Cell viability was assayed by colony formation assay.
RESULTS: The taxol resistant sub-lines (CNE1/Taxol, HNE2/Taxol and 5-8F/Taxol) developed displayed an average 5~8-fold higher IC50 value than their parental cells. The common losses of chromosome 18, 10q11-qter and gains of chromosome 12, 3q21-qter, 5p13-pter and 20q11-qter were observed by CGH in all of 6 NPC cell lines. A common gain region of chromosome 8q21-qter was identified in taxol resistant sub-lines. 15 genes of 762 transcripts on this chromosome region were consistently up-regulated detected by cDNA microarray in three taxol resistant sub-lines, and functionally clustered into various groups, including genes related to vascular formation vascular formation (ANGPT1), apoptosis (MYC, TOP1MT), cell adhesion and cell cycle (PPP1R16A, SDC2, CA2, ANKRD46), gene regulation (HRSP12, ZNF696, SLC39A4, POP1), metabolism (PYCRL). Inhibition of ANGPT1 expression significantly increased the sensitivity of CNE-1/taxol to paclitaxol.
CONCLUSION: The common gain of chromosome 8q21-qter in taxol resistant sublines predicates that potential candidate genes on this region may contribute to taxol resistant phenotype. ANGPT1 may be associated with taxol resistance of NPC cells.

Entities:  

Keywords:  Angiopoietin; chromosome imbalance; drug resistance; nasopharyngeal carcinoma

Mesh:

Substances:

Year:  2015        PMID: 26722421      PMCID: PMC4680366     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  37 in total

1.  Origin of multidrug resistance in cells with and without multidrug resistance genes: chromosome reassortments catalyzed by aneuploidy.

Authors:  P Duesberg; R Stindl; R Hehlmann
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-11       Impact factor: 11.205

2.  Inhibition of α folate receptor resulting in a reversal of taxol resistance in nasopharyngeal carcinoma.

Authors:  Wei Li; Guolin Tan; Yanhong Ma; Heqing Li; Guangxiang He
Journal:  Otolaryngol Head Neck Surg       Date:  2011-10-31       Impact factor: 3.497

3.  Paclitaxel, cisplatin, and 5-fluorouracil for patients with advanced or recurrent squamous cell carcinoma of the head and neck.

Authors:  M Hussain; S Gadgeel; O Kucuk; W Du; W Salwen; J Ensley
Journal:  Cancer       Date:  1999-12-01       Impact factor: 6.860

4.  Tie-2 and angiopoietin-1 expression in human thyroid tumors.

Authors:  N Mitsutake; H Namba; K Takahara; K Ishigaki; J Ishigaki; H Ayabe; S Yamashita
Journal:  Thyroid       Date:  2002-02       Impact factor: 6.568

5.  Mechanism of differential sensitivity to cisplatin in nasopharyngeal carcinoma cells.

Authors:  X Wang; J R Masters; Y C Wong; A K Lo; S W Tsao
Journal:  Anticancer Res       Date:  2001 Jan-Feb       Impact factor: 2.480

6.  Angiopoietins promote ovarian cancer progression by establishing a procancer microenvironment.

Authors:  Melissa K Brunckhorst; Yin Xu; Rong Lu; Qin Yu
Journal:  Am J Pathol       Date:  2014-08       Impact factor: 4.307

Review 7.  Targeting the ANGPT-TIE2 pathway in malignancy.

Authors:  Hanhua Huang; Abhijit Bhat; Gary Woodnutt; Rodney Lappe
Journal:  Nat Rev Cancer       Date:  2010-08       Impact factor: 60.716

8.  1p31, 7q21 and 18q21 chromosomal aberrations and candidate genes in acquired vinblastine resistance of human cervical carcinoma KB cells.

Authors:  Jin Wang; Lai-Shan Tai; Chi-Hung Tzang; Wan Fong Fong; Xin-Yuan Guan; Mengsu Yang
Journal:  Oncol Rep       Date:  2008-05       Impact factor: 3.906

Review 9.  Molecular control of angiopoietin signalling.

Authors:  Harprit Singh; Tariq A Tahir; Deborah O A Alawo; Eyad Issa; Nicholas P J Brindle
Journal:  Biochem Soc Trans       Date:  2011-12       Impact factor: 5.407

10.  Molecular characterization of acquired tolerance of tumor cells to picropodophyllin (PPP).

Authors:  Jamileh Hashemi; Claire Worrall; Daiana Vasilcanu; Mårten Fryknäs; Luqman Sulaiman; Mohsen Karimi; Wen-Hui Weng; Weng-Onn Lui; Christina Rudduck; Magnus Axelson; Helena Jernberg-Wiklund; Leonard Girnita; Olle Larsson; Catharina Larsson
Journal:  PLoS One       Date:  2011-03-14       Impact factor: 3.240

View more
  4 in total

Review 1.  Structure, biochemistry, and gene expression patterns of the proline biosynthetic enzyme pyrroline-5-carboxylate reductase (PYCR), an emerging cancer therapy target.

Authors:  Alexandra N Bogner; Kyle M Stiers; John J Tanner
Journal:  Amino Acids       Date:  2021-05-18       Impact factor: 3.520

2.  Optimization, Characterization and in vivo Evaluation of Paclitaxel-Loaded Folate-Conjugated Superparamagnetic Iron Oxide Nanoparticles.

Authors:  Gang Gui; Ziqi Fan; Yihuan Ning; Cancan Yuan; Baolin Zhang; Qin Xu
Journal:  Int J Nanomedicine       Date:  2021-03-19

Review 3.  Isozymes of P5C reductase (PYCR) in human diseases: focus on cancer.

Authors:  Chien-An A Hu
Journal:  Amino Acids       Date:  2021-07-22       Impact factor: 3.520

4.  Epigenetic Changes in Neonates Born to Mothers With Gestational Diabetes Mellitus May Be Associated With Neonatal Hypoglycaemia.

Authors:  Yoshifumi Kasuga; Tomoko Kawai; Kei Miyakoshi; Yoshifumi Saisho; Masumi Tamagawa; Keita Hasegawa; Satoru Ikenoue; Daigo Ochiai; Mariko Hida; Mamoru Tanaka; Kenichiro Hata
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-29       Impact factor: 5.555

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.